TY - JOUR T1 - An international multicenter examination of MOG antibody assays JF - medRxiv DO - 10.1101/19011049 SP - 19011049 AU - Markus Reindl AU - Kathrin Schanda AU - Mark Woodhall AU - Fiona Tea AU - Sudarshini Ramanathan AU - Jessica Sagen AU - Jim Fryer AU - John Mills AU - Bianca Teegen AU - Swantje Mindorf AU - Nora Ritter AU - Ulrike Krummrei AU - Winfried Stöcker AU - Juliane Eggert AU - Eoin P. Flanagan AU - Melanie Ramberger AU - Harald Hegen AU - Kevin Rostasy AU - Thomas Berger AU - Maria Isabel Leite AU - Jacqueline Palace AU - Sarosh R. Irani AU - Russell C. Dale AU - Christian Probst AU - Monika Probst AU - Fabienne Brilot AU - Sean Pittock AU - Patrick Waters Y1 - 2019/01/01 UR - http://medrxiv.org/content/early/2019/11/22/19011049.abstract N2 - Objectives To compare the reproducibility of 11 antibody assays for IgG and IgM myelin oligodendrocyte glycoprotein antibodies (MOG-IgG, MOG-IgM) from five international centers.Methods The following samples were analyzed: MOG-IgG clearly positive sera (n=39), MOG-IgG low positive sera (n=39), borderline negative sera (n=13), clearly negative sera (n=40), and healthy blood donors (n=30). As technical controls, 18 replicates (9 MOG-IgG positive and 9 negative) were included. All samples and controls were re-coded, aliquoted, and distributed to the five testing centers which performed the following antibody assays: five live and one fixed immunofluorescence cell-based assays (CBA-IF, five MOG-IgG, one MOG-IgM), three live flow cytometry cell-based assays (FACS-CBA, all MOG-IgG), and two enzyme-linked immunosorbent assays (ELISA, both MOG-IgG).Results We found excellent agreement (96%) between the live CBAs for MOG-IgG for samples previously identified as clearly positive or negative from four different national testing centers. The agreement was lower with fixed CBA-IF (90%) and the ELISA showed no concordance with CBAs for detection of human MOG-IgG. All CBAs showed excellent inter-assay reproducibility. The agreement of MOG-IgG CBAs for borderline negative (77%) and particularly low positive (33%) samples was less good. Finally, most samples from healthy blood donors (97%) were negative for MOG-IgG in all CBAs.Conclusion Live MOG-IgG CBAs showed excellent agreement for high positive and very good agreement for negative samples at four international testing centers. Low positive samples were more frequently discordant than in similar assays for other autoantigens. Further research is needed to improve international standardization for clinical care.Competing Interest StatementMarkus Reindl was supported by a research grant from the Austrian Science Promotion Agency (FFG). The University Hospital and Medical University of Innsbruck (Austria; M.R.) receives payments for antibody assays (MOG, AQP4, and other autoantibodies) and for MOG and AQP4 antibody validation experiments organized by Euroimmun (Lübeck, Germany). Kathrin Schanda was supported by a research grant from the Austrian Science Promotion Agency (FFG). Mark Woodhall has no disclosure to report. Fiona Tea has no disclosure to report. Sudarshini Ramanathan has received research funding from the National Health and Medical Research Council (Australia), the Petre Foundation (Australia), and the Brain Foundation (Australia); and has served as a non-remunerated consultant in an advisory board for UCB. Jessica Sagen has no disclosure to report. Jim Fryer has no disclosure to report. John Mills has no disclosure to report. Eoin P. Flanagan receives research support as a site principal investigator in a randomized placebo-controlled clinical trial of Inebilizumab (a CD19 inhibitor) in neuromyelitis optica spectrum disorders funded by MedImmune/Viela Bio. Bianca Teegen has received personal compensation from Labor Dr. Stöcker as an employee. Swantje Mindorf has received personal compensation from Euroimmun AG as an employee. Nora Ritter has received personal compensation from Euroimmun AG as an employee. Ulrike Krummrei has received personal compensation from Euroimmun AG as an employee. Winfried Stöcker has received personal compensation from Euroimmun AG as CEO. Juliane Eggert has received personal compensation from Euroimmun as an employee of the Institute for Quality Assurance. Melanie Ramberger was supported by a research grant from the Austrian Science Promotion Agency (FFG). Harald Hegen has participated in meetings sponsored by, received speaker honoraria or travel funding from Bayer, Biogen, Merck, Novartis, Sanofi-Genzyme, Siemens, Teva, and received honoraria for acting as consultant for Teva. Kevin Rostasy has received honoraria from Novartis and Merck as invited speaker and served as consultant for the PARADIGM Study/Novartis. Thomas Berger has participated in meetings sponsored by and received honoraria (lectures, advisory boards, consultations) from pharmaceutical companies marketing treatments for multiple sclerosis: Almirall, Bayer, Biogen, Biologix, Bionorica, Genzyme, MedDay, Merck, Novartis, Octapharma, Roche, Sanofi/Genzyme, TG Pharmaceuticals, TEVA-ratiopharm and UCB. His institution has received financial support in the last 12 months by unrestricted research grants (Biogen, Bayer, Merck, Novartis, Sanofi/Genzyme, and TEVA ratiopharm) and for participation in clinical trials in multiple sclerosis sponsored by Alexion, Bayer, Biogen, Merck, Novartis, Octapharma, Roche, Sanofi/Genzyme, and TEVA. Maria Isabel Leite reported being involved in aquaporin-4 testing, receiving support from the National Health Service National Specialised Commissioning Group for Neuromyelitis Optica and the National Institute for Health Research Oxford Biomedical Research Centre, receiving speaking honoraria from Biogen Idec, and receiving travel grants from Novartis. Jacqueline Palace is partly funded by highly specialized services to run a national congenital myasthenia service and a neuromyelitis service. She has received support for scientific meetings and honorariums for advisory work from Merck Serono, Biogen Idec, Novartis, Teva, Chugai Pharma and Bayer Schering, Alexion, Roche, Genzyme, MedImmune, EuroImmun, MedDay, Abide ARGENX, UCB and Viela Bio and grants from Merck Serono, Novartis, Biogen Idec, Teva, Abide, MedImmune, Bayer Schering, Genzyme, Chugai and Alexion. She has received grants from the MS society, Guthrie Jackson Foundation, NIHR, Oxford Health Services Research Committee, EDEN, MRC, GMSI, John Fell and Myaware for research studies. Sarosh R Irani reports personal fees from MedImmune and has a patent WO/2010/046716 entitled ‘Neurological Autoimmune Disorders’ with royalties paid. Russell Dale was supported by research grants from the National Health and Medical Research Council (NHRMC), Multiple Sclerosis Research Australia (MSRA), and the Sydney Research Excellence Initiative 2020 (The University of Sydney, Australia). He has received honoraria from Biogen Idec and Merck Serono as invited speaker. Christian Probst has received personal compensation from Euroimmun AG as an employee. Monika Probst has received personal compensation from Euroimmun AG as an employee of the Institute for Quality Assurance. Fabienne Brilot was supported by research grants from the National Health and Medical Research Council (NHRMC), Multiple Sclerosis Research Australia (MSRA), and the Sydney Research Excellence Initiative 2020 (The University of Sydney, Australia). She has received honoraria from Biogen Idec and Merck Serono as invited speaker. Sean Pittock is a named inventor on filed patents that relate to functional AQP4/NMO-IgG assays and NMO-IgG as a cancer marker. He has a patent pending for Septin 5, GFAP, PDE10A, Kelch-11 and MAP1B IgGs as markers of neurological autoimmunity and paraneoplastic disorders. He has consulted for Alexion, Medimmune, UCB and Astellas. He has received research support from Grifols, Medimmune, and Alexion. All compensation for consulting activities is paid directly to Mayo Clinic. Patrick Waters and the University of Oxford are named inventors on patents for antibody assays and have received royalties. He has received honoraria or research funding from Biogen Idec, Mereo biopharma, Retrogenix and Euroimmun AG, and travel grants from the Guthy-Jackson Charitable Foundation.Funding StatementThis study was supported by research grants from the Austrian Research Promoting Society (FFG Bridge 1 project Nr. 853209, Markus Reindl), the Austrian Science Fund (FWF projects P32699 (Markus Reindl) and J4157-B30 (Melanie Ramberger)), the National Health and Medical Research Council (Australia), Multiple Sclerosis Research Australia, and the Sydney Research Excellence Initiative 2020 (The University of Sydney, Australia).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe dataset used and analyzed during the current study is included in the main text and the supplementary files.ADEMacute disseminated encephalomyelitisAQP4aquaporin-4CBAcell-based assayELISAenzyme linked immunosorbent assayFACSfluorescence activated cell sortingIFimmunofluorescenceMOGmyelin oligodendrocyte glycoproteinMSmultiple sclerosisNMOSDneuromyelitis optica spectrum disorderONoptic neuritis. ER -